GlaxoSmithKline's chief strategist of research and development Yvonne Greenstreet decided to become a doctor at age seven, after watching a physician make the rounds in her native Ghana. She moved to the "cold, somewhat drearier stiff upper lip environment" of England for boarding school and completed a residency in obstetrics and gynecology, but soon became frustrated with the UK health care system. After earning an MBA in France, she moved to Glaxo in 1992. In "Change Broker", she explains how the pharmaceutical giant is shaking up its R&D structure. Rather than focusing on "small incremental improvements," the company is seeking "wholesale change" in both the science and business of drug development, she says.
Ellen Raphael is the director of the UK-based Sense about Science campaign, which educates the public about evidence-based science. After earning an MA in social research from the University of Kent in England, Raphael says she "became ...
